Copyright Reports & Markets. All rights reserved.

Global Monoclonal Antibody Medicine Market 2026 by Company, Regions, Type and Application, Forecast to 2032

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Classification of Monoclonal Antibody Medicine by Type
    • 1.3.1 Overview: Global Monoclonal Antibody Medicine Market Size by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 Global Monoclonal Antibody Medicine Consumption Value Market Share by Type in 2025
    • 1.3.3 Biologics
    • 1.3.4 Biosimilars
  • 1.4 Global Monoclonal Antibody Medicine Market by Application
    • 1.4.1 Overview: Global Monoclonal Antibody Medicine Market Size by Application: 2021 Versus 2025 Versus 2032
    • 1.4.2 Cancer
    • 1.4.3 Autoimmune Disease
    • 1.4.4 Other
  • 1.5 Global Monoclonal Antibody Medicine Market Size & Forecast
  • 1.6 Global Monoclonal Antibody Medicine Market Size and Forecast by Region
    • 1.6.1 Global Monoclonal Antibody Medicine Market Size by Region: 2021 VS 2025 VS 2032
    • 1.6.2 Global Monoclonal Antibody Medicine Market Size by Region, (2021-2032)
    • 1.6.3 North America Monoclonal Antibody Medicine Market Size and Prospect (2021-2032)
    • 1.6.4 Europe Monoclonal Antibody Medicine Market Size and Prospect (2021-2032)
    • 1.6.5 Asia-Pacific Monoclonal Antibody Medicine Market Size and Prospect (2021-2032)
    • 1.6.6 South America Monoclonal Antibody Medicine Market Size and Prospect (2021-2032)
    • 1.6.7 Middle East & Africa Monoclonal Antibody Medicine Market Size and Prospect (2021-2032)

2 Company Profiles

  • 2.1 Roche
    • 2.1.1 Roche Details
    • 2.1.2 Roche Major Business
    • 2.1.3 Roche Monoclonal Antibody Medicine Product and Solutions
    • 2.1.4 Roche Monoclonal Antibody Medicine Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 Roche Recent Developments and Future Plans
  • 2.2 Amgen
    • 2.2.1 Amgen Details
    • 2.2.2 Amgen Major Business
    • 2.2.3 Amgen Monoclonal Antibody Medicine Product and Solutions
    • 2.2.4 Amgen Monoclonal Antibody Medicine Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 Amgen Recent Developments and Future Plans
  • 2.3 AbbVie
    • 2.3.1 AbbVie Details
    • 2.3.2 AbbVie Major Business
    • 2.3.3 AbbVie Monoclonal Antibody Medicine Product and Solutions
    • 2.3.4 AbbVie Monoclonal Antibody Medicine Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 AbbVie Recent Developments and Future Plans
  • 2.4 Sanofi
    • 2.4.1 Sanofi Details
    • 2.4.2 Sanofi Major Business
    • 2.4.3 Sanofi Monoclonal Antibody Medicine Product and Solutions
    • 2.4.4 Sanofi Monoclonal Antibody Medicine Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 Sanofi Recent Developments and Future Plans
  • 2.5 Johnson & Johnson
    • 2.5.1 Johnson & Johnson Details
    • 2.5.2 Johnson & Johnson Major Business
    • 2.5.3 Johnson & Johnson Monoclonal Antibody Medicine Product and Solutions
    • 2.5.4 Johnson & Johnson Monoclonal Antibody Medicine Revenue, Gross Margin and Market Share (2021-2026)
    • 2.5.5 Johnson & Johnson Recent Developments and Future Plans
  • 2.6 Pfizer
    • 2.6.1 Pfizer Details
    • 2.6.2 Pfizer Major Business
    • 2.6.3 Pfizer Monoclonal Antibody Medicine Product and Solutions
    • 2.6.4 Pfizer Monoclonal Antibody Medicine Revenue, Gross Margin and Market Share (2021-2026)
    • 2.6.5 Pfizer Recent Developments and Future Plans
  • 2.7 Eli Lilly
    • 2.7.1 Eli Lilly Details
    • 2.7.2 Eli Lilly Major Business
    • 2.7.3 Eli Lilly Monoclonal Antibody Medicine Product and Solutions
    • 2.7.4 Eli Lilly Monoclonal Antibody Medicine Revenue, Gross Margin and Market Share (2021-2026)
    • 2.7.5 Eli Lilly Recent Developments and Future Plans
  • 2.8 Novartis
    • 2.8.1 Novartis Details
    • 2.8.2 Novartis Major Business
    • 2.8.3 Novartis Monoclonal Antibody Medicine Product and Solutions
    • 2.8.4 Novartis Monoclonal Antibody Medicine Revenue, Gross Margin and Market Share (2021-2026)
    • 2.8.5 Novartis Recent Developments and Future Plans
  • 2.9 Merck
    • 2.9.1 Merck Details
    • 2.9.2 Merck Major Business
    • 2.9.3 Merck Monoclonal Antibody Medicine Product and Solutions
    • 2.9.4 Merck Monoclonal Antibody Medicine Revenue, Gross Margin and Market Share (2021-2026)
    • 2.9.5 Merck Recent Developments and Future Plans
  • 2.10 Biogen
    • 2.10.1 Biogen Details
    • 2.10.2 Biogen Major Business
    • 2.10.3 Biogen Monoclonal Antibody Medicine Product and Solutions
    • 2.10.4 Biogen Monoclonal Antibody Medicine Revenue, Gross Margin and Market Share (2021-2026)
    • 2.10.5 Biogen Recent Developments and Future Plans
  • 2.11 Celltrion
    • 2.11.1 Celltrion Details
    • 2.11.2 Celltrion Major Business
    • 2.11.3 Celltrion Monoclonal Antibody Medicine Product and Solutions
    • 2.11.4 Celltrion Monoclonal Antibody Medicine Revenue, Gross Margin and Market Share (2021-2026)
    • 2.11.5 Celltrion Recent Developments and Future Plans
  • 2.12 Sobi
    • 2.12.1 Sobi Details
    • 2.12.2 Sobi Major Business
    • 2.12.3 Sobi Monoclonal Antibody Medicine Product and Solutions
    • 2.12.4 Sobi Monoclonal Antibody Medicine Revenue, Gross Margin and Market Share (2021-2026)
    • 2.12.5 Sobi Recent Developments and Future Plans
  • 2.13 3SBIO
    • 2.13.1 3SBIO Details
    • 2.13.2 3SBIO Major Business
    • 2.13.3 3SBIO Monoclonal Antibody Medicine Product and Solutions
    • 2.13.4 3SBIO Monoclonal Antibody Medicine Revenue, Gross Margin and Market Share (2021-2026)
    • 2.13.5 3SBIO Recent Developments and Future Plans
  • 2.14 Innovent Biologics
    • 2.14.1 Innovent Biologics Details
    • 2.14.2 Innovent Biologics Major Business
    • 2.14.3 Innovent Biologics Monoclonal Antibody Medicine Product and Solutions
    • 2.14.4 Innovent Biologics Monoclonal Antibody Medicine Revenue, Gross Margin and Market Share (2021-2026)
    • 2.14.5 Innovent Biologics Recent Developments and Future Plans

3 Market Competition, by Players

  • 3.1 Global Monoclonal Antibody Medicine Revenue and Share by Players (2021-2026)
  • 3.2 Market Share Analysis (2025)
    • 3.2.1 Market Share of Monoclonal Antibody Medicine by Company Revenue
    • 3.2.2 Top 3 Monoclonal Antibody Medicine Players Market Share in 2025
    • 3.2.3 Top 6 Monoclonal Antibody Medicine Players Market Share in 2025
  • 3.3 Monoclonal Antibody Medicine Market: Overall Company Footprint Analysis
    • 3.3.1 Monoclonal Antibody Medicine Market: Region Footprint
    • 3.3.2 Monoclonal Antibody Medicine Market: Company Product Type Footprint
    • 3.3.3 Monoclonal Antibody Medicine Market: Company Product Application Footprint
  • 3.4 New Market Entrants and Barriers to Market Entry
  • 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

  • 4.1 Global Monoclonal Antibody Medicine Consumption Value and Market Share by Type (2021-2026)
  • 4.2 Global Monoclonal Antibody Medicine Market Forecast by Type (2027-2032)

5 Market Size Segment by Application

  • 5.1 Global Monoclonal Antibody Medicine Consumption Value Market Share by Application (2021-2026)
  • 5.2 Global Monoclonal Antibody Medicine Market Forecast by Application (2027-2032)

6 North America

  • 6.1 North America Monoclonal Antibody Medicine Consumption Value by Type (2021-2032)
  • 6.2 North America Monoclonal Antibody Medicine Market Size by Application (2021-2032)
  • 6.3 North America Monoclonal Antibody Medicine Market Size by Country
    • 6.3.1 North America Monoclonal Antibody Medicine Consumption Value by Country (2021-2032)
    • 6.3.2 United States Monoclonal Antibody Medicine Market Size and Forecast (2021-2032)
    • 6.3.3 Canada Monoclonal Antibody Medicine Market Size and Forecast (2021-2032)
    • 6.3.4 Mexico Monoclonal Antibody Medicine Market Size and Forecast (2021-2032)

7 Europe

  • 7.1 Europe Monoclonal Antibody Medicine Consumption Value by Type (2021-2032)
  • 7.2 Europe Monoclonal Antibody Medicine Consumption Value by Application (2021-2032)
  • 7.3 Europe Monoclonal Antibody Medicine Market Size by Country
    • 7.3.1 Europe Monoclonal Antibody Medicine Consumption Value by Country (2021-2032)
    • 7.3.2 Germany Monoclonal Antibody Medicine Market Size and Forecast (2021-2032)
    • 7.3.3 France Monoclonal Antibody Medicine Market Size and Forecast (2021-2032)
    • 7.3.4 United Kingdom Monoclonal Antibody Medicine Market Size and Forecast (2021-2032)
    • 7.3.5 Russia Monoclonal Antibody Medicine Market Size and Forecast (2021-2032)
    • 7.3.6 Italy Monoclonal Antibody Medicine Market Size and Forecast (2021-2032)

8 Asia-Pacific

  • 8.1 Asia-Pacific Monoclonal Antibody Medicine Consumption Value by Type (2021-2032)
  • 8.2 Asia-Pacific Monoclonal Antibody Medicine Consumption Value by Application (2021-2032)
  • 8.3 Asia-Pacific Monoclonal Antibody Medicine Market Size by Region
    • 8.3.1 Asia-Pacific Monoclonal Antibody Medicine Consumption Value by Region (2021-2032)
    • 8.3.2 China Monoclonal Antibody Medicine Market Size and Forecast (2021-2032)
    • 8.3.3 Japan Monoclonal Antibody Medicine Market Size and Forecast (2021-2032)
    • 8.3.4 South Korea Monoclonal Antibody Medicine Market Size and Forecast (2021-2032)
    • 8.3.5 India Monoclonal Antibody Medicine Market Size and Forecast (2021-2032)
    • 8.3.6 Southeast Asia Monoclonal Antibody Medicine Market Size and Forecast (2021-2032)
    • 8.3.7 Australia Monoclonal Antibody Medicine Market Size and Forecast (2021-2032)

9 South America

  • 9.1 South America Monoclonal Antibody Medicine Consumption Value by Type (2021-2032)
  • 9.2 South America Monoclonal Antibody Medicine Consumption Value by Application (2021-2032)
  • 9.3 South America Monoclonal Antibody Medicine Market Size by Country
    • 9.3.1 South America Monoclonal Antibody Medicine Consumption Value by Country (2021-2032)
    • 9.3.2 Brazil Monoclonal Antibody Medicine Market Size and Forecast (2021-2032)
    • 9.3.3 Argentina Monoclonal Antibody Medicine Market Size and Forecast (2021-2032)

10 Middle East & Africa

  • 10.1 Middle East & Africa Monoclonal Antibody Medicine Consumption Value by Type (2021-2032)
  • 10.2 Middle East & Africa Monoclonal Antibody Medicine Consumption Value by Application (2021-2032)
  • 10.3 Middle East & Africa Monoclonal Antibody Medicine Market Size by Country
    • 10.3.1 Middle East & Africa Monoclonal Antibody Medicine Consumption Value by Country (2021-2032)
    • 10.3.2 Turkey Monoclonal Antibody Medicine Market Size and Forecast (2021-2032)
    • 10.3.3 Saudi Arabia Monoclonal Antibody Medicine Market Size and Forecast (2021-2032)
    • 10.3.4 UAE Monoclonal Antibody Medicine Market Size and Forecast (2021-2032)

11 Market Dynamics

  • 11.1 Monoclonal Antibody Medicine Market Drivers
  • 11.2 Monoclonal Antibody Medicine Market Restraints
  • 11.3 Monoclonal Antibody Medicine Trends Analysis
  • 11.4 Porters Five Forces Analysis
    • 11.4.1 Threat of New Entrants
    • 11.4.2 Bargaining Power of Suppliers
    • 11.4.3 Bargaining Power of Buyers
    • 11.4.4 Threat of Substitutes
    • 11.4.5 Competitive Rivalry

12 Industry Chain Analysis

  • 12.1 Monoclonal Antibody Medicine Industry Chain
  • 12.2 Monoclonal Antibody Medicine Upstream Analysis
  • 12.3 Monoclonal Antibody Medicine Midstream Analysis
  • 12.4 Monoclonal Antibody Medicine Downstream Analysis

13 Research Findings and Conclusion

    14 Appendix

    • 14.1 Methodology
    • 14.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Monoclonal Antibody Medicine market size was valued at US$ 294710 million in 2025 and is forecast to a readjusted size of US$ 634870 million by 2032 with a CAGR of 11.7% during review period.
    Monoclonal antibodies are immune system proteins that are created in the lab. Antibodies are produced naturally by your body and help the immune system recognize germs that cause disease, such as bacteria and viruses, and mark them for destruction. Like your body’s own antibodies, monoclonal antibodies recognize specific targets.
    The monoclonal antibody medicine market is driven by the growing demand for targeted and personalized therapies and the significant advancements in biotechnology and antibody engineering. Monoclonal antibodies (mAbs) offer precise targeting of specific antigens, making them highly effective in treating various diseases, including cancer, autoimmune disorders, and infectious diseases. Their ability to modulate the immune response and their potential for fewer side effects compared to traditional treatments have fueled their popularity among healthcare providers and patients. Moreover, the development of novel mAbs and the expansion of approved indications for existing therapies further contribute to market growth. However, the market also faces challenges, including the high cost of mAb therapies, which can limit patient access and reimbursement. Additionally, the complex manufacturing process and regulatory requirements for mAb medicines can be obstacles for new market entrants. To succeed in this competitive market, manufacturers must focus on improving affordability, exploring biosimilar opportunities, and investing in research and development to develop innovative and differentiated monoclonal antibody medicines that address unmet medical needs.
    This report is a detailed and comprehensive analysis for global Monoclonal Antibody Medicine market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global Monoclonal Antibody Medicine market size and forecasts, in consumption value ($ Million), 2021-2032
    Global Monoclonal Antibody Medicine market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
    Global Monoclonal Antibody Medicine market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
    Global Monoclonal Antibody Medicine market shares of main players, in revenue ($ Million), 2021-2026
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Monoclonal Antibody Medicine
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Monoclonal Antibody Medicine market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Roche, Amgen, AbbVie, Sanofi, Johnson & Johnson, Pfizer, Eli Lilly, Novartis, Merck, Biogen, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market segmentation
    Monoclonal Antibody Medicine market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    Biologics
    Biosimilars
    Market segment by Application
    Cancer
    Autoimmune Disease
    Other
    Market segment by players, this report covers
    Roche
    Amgen
    AbbVie
    Sanofi
    Johnson & Johnson
    Pfizer
    Eli Lilly
    Novartis
    Merck
    Biogen
    Celltrion
    Sobi
    3SBIO
    Innovent Biologics
    Market segment by regions, regional analysis covers
    North America (United States, Canada and Mexico)
    Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
    Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
    South America (Brazil, Rest of South America)
    Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 13 chapters:
    Chapter 1, to describe Monoclonal Antibody Medicine product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top players of Monoclonal Antibody Medicine, with revenue, gross margin, and global market share of Monoclonal Antibody Medicine from 2021 to 2026.
    Chapter 3, the Monoclonal Antibody Medicine competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
    Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
    Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and Monoclonal Antibody Medicine market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
    Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
    Chapter 12, the key raw materials and key suppliers, and industry chain of Monoclonal Antibody Medicine.
    Chapter 13, to describe Monoclonal Antibody Medicine research findings and conclusion.

    Buy now